Bipolardisorder is a mood disorder characterised by manic, hypomanic and depressive episodes ( Frye 2011 ). Pharmacological treatment is crucial. Such treatment is aimed for acute exacerbation of a manic, hypomanic or depressive episode, preventing relapses and recurrences and improving inter-episode functioning (remission/recovery) ( Jarema et al. 2005 ).
The medications used to treat this disorder include mood stabilisers (lithium and anticonvulsants), antipsychotics (typical and atypical), antidepressants, hypnotics and anxiolytics
Pichai Ittasakul, Shefali Miller, Po W. Wang, Shelley J. Hill, Meredith E. Childers and Terence A. Ketter
1. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007; 64:543-52.
2. World Health Organization. The World Health Report 2001 - Mental Health: New Understanding, New Hope. Geneva, Switzerland.: World Helath Organization; 2001.
3. Ketter TA. Handbook of diagnosis and treatment of bipolardisorder. Washington, DC: American Psychiatric
Milin Miruna, Lăzărescu M, Racolţa Anca, Silvoșeanu C and Bredicean Cristina
1. Maier W, Zobel A, Wagner M. Schizophrenia and BipolarDisorder: Differences and Overlaps. Curr Opin Psychiatry. 2006;19(2):165-170.
2. Korn ML. Schizophrenia and BipolarDisorder: An Evolving Interface. Medscape Psychiatry & Mental Health. 2004;9(2)
3. Lake CR, Hurwitz N. Schizoaffective disorder merges schizophrenia and bipolardisorders as one disease - there is no schizoaffective disorder. Curr Opin Psychiatry. 2007;20(4):365-79.
4. Harrow M, et al. Ten-year outcome:patients with
Ozlem Gurbuz, Kursat Altinbas, Ceyhan Oflezer, Erhan Kurt and Mehtap Delice Arslan
, prevalence and impact of bipolardisorder. J Clin Psychiatry, 2010;71(6):e14.
15. Geddes JR, Miklowitz DJ. Treatment of bipolardisorder. Lancet, 2013;381:1672-1682.
16. Woods, SW. The economic burden of bipolar disease. J Clin Psychiatry, 2000;13,38-41.
17. Matevosyan NR. Oral health of adults with serious mental illness: a review. Community Ment Health J, 2010;46:553-562.
18. Lavigne GJ, Kato T, Kolta A, Sessle BJ. Neurobiological mechanisms involved in sleep bruxism. Crit Rev Oral Biol Med, 2003
Olga Nowacka, Henryk Welcz and Hanna Karakuła-Juchnowicz
23. Runco M. Creativity. Annu. Rev. Psychol. 2004; 55:657-87.
24. Akiskal H.S, Akiskal K. Re-assessing the prevalence of bipolardisorders: clinical significance and artistic creativity. Psychiatry Psychobiol. 3 European Psychiatry. 1988.
25. Richards, Ruth, Kinney, Dennis K, Lunde, Inge, Benet, Maria, Merzel, Ann P.C. Creativity in manic-depressives, cyclothymes, their normal relatives, and control subjects. J. Abnorm. Psychol. 1988; 97 (3): 281-288.
26. Sass L.A. Schizophrenia, Modernism, and the "Creative
opening times, meal and prayer times ( Bahammam 2006 ).
Sleep has been shown to be affected in many psychiatric disorders: Patients with depression often suffer interrupted sleep and sleep-onset rapid eye movement periods. Poor sleep may be an early sign or a trigger of depression and manic episodes in bipolardisorder. Sleep deprivation has been used as a therapy for severe depressive disorders. During manic episodes, the need for sleep is known to be reduced. Temporary sleep changes have been observed during Ramadan ( Leiper et al 2008 ). Most of the effects of
American Psychiatric Association (APA), Steering Committee on Practice Guidelines. Practice Guideline for the Treatment of Patients with BipolarDisorder (April, 2002; 2 nd edition November, 2005). Web. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/bipolar.pdf
Amnesty International. Annual Report, China (2013). Web. http://www.amnestyusa.org/our-work/countries/asia-and-the-pacific/china
Australia Set to Block China Purchase of Iconic Cattle Ranch , AG Web and “Bloomberg News” (April, 2016). Web. http
Ewelina Dziwota, Barbara Drapala, Magdalena Gaj, Nikodem Skoczen and Marcin Olajossy
disorder: A double-blind randomized placebo controlled trial. Berk et al. BMC Med., 10, 91, 2012.
4. Berk M. et al.: The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: An open label trial. J. Affect. Disord., 135, 389, 2011.
5. Dell’Osso B. et al.: Superior chronic tolerability of adjunctive modafinil compared to pramipexole in treatment-resistant bipolardisorder. J. Affect. Disord., 150, 130, 2013.
6. Fan A. et al.: Allopurinol augmentation in the outpatient treatment of bipolar mania: a
Zorica Naumovska, Aleksandra K. Nestorovska, Zoran Sterjev, Ana Filipce, Aleksandra Grozdanova, Aleksandar Dimovski, Ljubica Suturkova and Vladimir Serafimoski
caudate of elderly patients with schizophrenia. Psychiatry Res. 2000;93:103–110.
16. Togo T, Akiyama H, Kondo H, Ikeda K., Kato M., Iseki E, Kosaka K. Expression of CD40 in the brain of Alzheimer’s disease and other neurological diseases. Brain Res. 2000; 885:117–121.
17. Padmos RC, Hillegers M H, Knijff EM, Vonk R., Bouvy A., Staal FJ, de RidderD, KupkaRW, Nolen WA, DrexhageHA. A discriminating messenger RNA signature for bipolardisorder formed by an aberrant expression of inflammatory genes in monocytes. Arch. Gen. Psychiatry 2008; 65:395–407.
genetics of schizophrenia. PLoS Med 2005; 2: e212.
6. Lichtenstein P, Yip BH, Bjork C, Pawitan Y, Cannon TD, Sullivan PF, et al. Common genetic determinants of schizophrenia and bipolardisorder in Swedish families: a population- based study. Lancet 2009; 373: 234-9.
7. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, et al. Common variants conferring risk of schizophrenia. Nature 2009; 460: 744-7.
8. Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Pe’er I, et al. Common variants on chromosome 6p22